OLMA:NASDAQ, Olema Pharmaceuticals, Inc.
OLMA stock overview
Olema Pharmaceuticals, Inc. (OLMA:NASDAQ) closed at $7.02 on November 20, 2026,
down 1.82% on the day.
The stock trades 80.6% below its 52-week high of $36.26
and 12.6% above its 52-week low of $6.24.
Over the past year, it lost 69.7%.
Olema Pharmaceuticals, Inc. is part of the Health Care sector.
Key figures
- Price
- $7.02
- Day change
- -1.82%
- Volume
- 1,256,470
- Average volume
- 1,266,089
- Market cap
- 614M+
- 52-week range
- $6.24 – $36.26
- 50-day average
- $7.90
- 200-day average
- $12.71
Price action over the past year
In 252 trading sessions since November 20, 2025, OLMA closed higher on 114 days (45%).
Its best day was December 10, 2025 (+15.43%) and its worst was March 9, 2026 (-25.75%).
The stock moved 10% or more in a single session 9 times.
It opened at least 5% above the previous day's high 1 time.
Recent signals
OLMA news
-
Nov 18, 2026:
Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposium
-
Nov 16, 2026:
Olema Oncology to Participate in Upcoming Investor Conferences
-
Nov 12, 2026:
Olema Oncology Announces Corporate Name Change
-
Nov 10, 2026:
Olema Oncology Reports Third Quarter 2026 Financial and Operating Results
-
Nov 4, 2026:
Olema Oncology to Present Combination Data from the Palazestrant and OP-3136 Programs at the 2026 San Antonio Breast Cancer Symposium
-
Nov 3, 2026:
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Oct 19, 2026:
The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology
-
Oct 16, 2026:
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250.
Similar stocks
Find more stocks like OLMA with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.